TD Asset Management Inc. lowered its stake in shares of United Therapeutics Corporation (NASDAQ:UTHR) by 0.1% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 33,178 shares of the biotechnology company’s stock after selling 40 shares during the period. TD Asset Management Inc. owned approximately 0.07% of United Therapeutics Corporation worth $4,492,000 as of its most recent filing with the SEC.

Several other hedge funds have also modified their holdings of the stock. First Trust Advisors LP raised its stake in shares of United Therapeutics Corporation by 92.8% in the third quarter. First Trust Advisors LP now owns 480,971 shares of the biotechnology company’s stock valued at $56,793,000 after buying an additional 231,502 shares in the last quarter. South Texas Money Management Ltd. purchased a new position in United Therapeutics Corporation during the third quarter valued at about $15,746,000. New Amsterdam Partners LLC NY increased its position in United Therapeutics Corporation by 9.8% in the third quarter. New Amsterdam Partners LLC NY now owns 46,408 shares of the biotechnology company’s stock valued at $5,480,000 after buying an additional 4,139 shares during the last quarter. Aviance Capital Partners LLC increased its position in United Therapeutics Corporation by 4.9% in the third quarter. Aviance Capital Partners LLC now owns 5,763 shares of the biotechnology company’s stock valued at $680,000 after buying an additional 271 shares during the last quarter. Finally, Lockheed Martin Investment Management Co. increased its position in United Therapeutics Corporation by 47.2% in the third quarter. Lockheed Martin Investment Management Co. now owns 37,400 shares of the biotechnology company’s stock valued at $4,416,000 after buying an additional 12,000 shares during the last quarter.

Institutional Ownership by Quarter for United Therapeutics Corporation (NASDAQ:UTHR)

Shares of United Therapeutics Corporation (NASDAQ:UTHR) traded down 0.43% on Friday, reaching $129.92. 578,775 shares of the company were exchanged. United Therapeutics Corporation has a 52-week low of $97.52 and a 52-week high of $169.89. The company has a market capitalization of $5.85 billion, a P/E ratio of 9.12 and a beta of 1.56. The stock has a 50 day moving average of $124.34 and a 200-day moving average of $138.37.

United Therapeutics Corporation (NASDAQ:UTHR) last posted its quarterly earnings results on Wednesday, April 26th. The biotechnology company reported $3.89 earnings per share for the quarter, topping the Zacks’ consensus estimate of $3.12 by $0.77. The company had revenue of $370.50 million for the quarter, compared to the consensus estimate of $399.59 million. United Therapeutics Corporation had a net margin of 41.04% and a return on equity of 34.74%. United Therapeutics Corporation’s revenue was up .4% on a year-over-year basis. During the same quarter last year, the firm posted $3.02 earnings per share. On average, analysts predict that United Therapeutics Corporation will post $14.42 EPS for the current fiscal year.

TRADEMARK VIOLATION WARNING: This piece was published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this piece on another website, it was stolen and reposted in violation of U.S. & international copyright & trademark legislation. The legal version of this piece can be viewed at https://www.thecerbatgem.com/2017/06/17/td-asset-management-inc-sells-40-shares-of-united-therapeutics-co-uthr-updated-updated.html.

Several research firms recently issued reports on UTHR. Jefferies Group LLC reissued a “sell” rating and issued a $105.00 target price on shares of United Therapeutics Corporation in a research report on Thursday, June 8th. ValuEngine downgraded United Therapeutics Corporation from a “strong-buy” rating to a “buy” rating in a research report on Friday, June 2nd. BidaskClub raised United Therapeutics Corporation from a “strong sell” rating to a “sell” rating in a research report on Friday, June 9th. Zacks Investment Research downgraded United Therapeutics Corporation from a “buy” rating to a “hold” rating in a research report on Monday, February 27th. Finally, Oppenheimer Holdings, Inc. reaffirmed a “buy” rating on shares of United Therapeutics Corporation in a research report on Monday, April 3rd. Three equities research analysts have rated the stock with a sell rating, nine have issued a hold rating and three have given a buy rating to the company. United Therapeutics Corporation has a consensus rating of “Hold” and an average target price of $137.09.

In other news, CEO Martine A. Rothblatt sold 1,240 shares of the stock in a transaction on Thursday, June 8th. The shares were sold at an average price of $129.60, for a total value of $160,704.00. Following the completion of the sale, the chief executive officer now owns 1,380 shares of the company’s stock, valued at $178,848. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Tommy G. Thompson sold 2,000 shares of the stock in a transaction on Wednesday, March 22nd. The stock was sold at an average price of $139.37, for a total transaction of $278,740.00. Following the completion of the sale, the director now directly owns 2,000 shares of the company’s stock, valued at approximately $278,740. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 17,020 shares of company stock worth $2,154,373. 7.50% of the stock is currently owned by insiders.

United Therapeutics Corporation Company Profile

United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Remodulin (treprostinil) Injection; Tyvaso (treprostinil) Inhalation Solution (Tyvaso); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca).

Receive News & Stock Ratings for United Therapeutics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics Corporation and related stocks with our FREE daily email newsletter.